Abstract Search

ea0090ep236 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Identification of predictors of severe hypoglycemia in adults with type 1 diabetes in andalusia (Spain): results of the multicenter study "Sehypan"

Rodriguez de Vera Gomez Pablo , Bellido Virginia , Dominguez-Lopez Marta , Roman Angel Rebollo , Fuentes Miguel Damas , Barea Almudena Lara , Baena Juan Manuel Guardia , Cozar Leon Maria Victoria , Sanchez Gomez Nancy , Ortega Maria del Carmen Ayala , Lopez Maria Lainez , Alcantara Laguna Maria Dolores , Martinez Ortega Antonio Jesus , Torres Enrique Redondo , Malo Carolina Sanchez , Autillo Juan Gayubo , Martinez-Brocca Maria Asuncion

Objectives: To describe modifiable sociodemographic and clinical risk factors predictive of severe hypoglycemia with need for urgent health care in adults with type 1 diabetes (T1DM).Methods: Multicenter, observational and retrospective study with case-control design.Cases: T1DM adults with severe hypoglycemia, defined as glycemia <70 mg/dl requiring urgent out-of-hospital health care for its resolution. Data source, geographic...

1 shares

ea0070aep462 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Effects of semaglutide on glycemic control and body composition in patients with type 2 diabetes mellitus and obesity in a real life setting in spain

luiza luca Bogdana , Miguel Sierra Poyatos Roberto , Cardenas Jersy , Sanchez Gomez Nancy , Jesus Silva Rodriguez Maria , Modroño Mostoles Naiara , Montoya Alvarez Teresa , Sanchez Lopez Raquel , Cruces Vega Eva , Estrella Alicia , Barrio Pilar , Sanchez Lechuga Begoña , Gonzalo Montesinos Irene , Jose De la Cruz Fernandez Maria , Perez Alvarez Enrique , Vazquez Martinez Clotilde

Introduction: Semaglutide is a GLP1 receptor agonist (GLP1RA) recently approved in Spain for the treatment of Type 2 Diabetes (T2D) and the National Health Service finances it for patients with T2D and body mass index (BMI) > 30 with a poor metabolic control with metformin.Objectives: Evaluate the effects of Semaglutide on glycemic control and body composition in patients with T2D (PwT2D) and obesity after 6 months of use in a real life setting.<...

0 shares

ea0070ep197 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Real world data of Type 2 Diabetes Mellitus (T2DM) obese patients using another GLP1 receptor agonist (GLP1–RA) and switching to Semaglutide in Spain

Cardenas Jersy , Sanchez Gomez Nancy , Miguel Sierra Poyatos Roberto , Luiza Luca Bogdana , Modroño Mostoles Naiara , Montoya Alvarez Teresa , Silva Rodriguez Maria Jesus , Ortega Juaristi Maite , Meneses González Diego , De Los Angeles Gonzalo Redondo Maria , Galdon Sanz–Pastor Alba , Ruiz Sanchez Jorge , De La Paz Gómez Montes María , Cruces Vega Cristina , Vazquez Martinez Clotilde

Objectives: Semaglutide was approved for the treatment of T2DM patients with a body mass index (BMI) > 30kg/m2 by the Spanish National Health Service in May 2019. We evaluate clinical outcomes of patients on previous treatment with any another GLP1–RA that switch to Semaglutide.Material and Methods: Retrospective analysis. Sixty–five T2DM patients were included. Demographic data, anthropometric, systolic blood pressure (SBP), d...

0 shares

Endocrine Abstracts

Identification of predictors of severe hypoglycemia in adults with type 1 diabetes in andalusia (Spain): results of the multicenter study "Sehypan"

Effects of semaglutide on glycemic control and body composition in patients with type 2 diabetes mellitus and obesity in a real life setting in spain

Real world data of Type 2 Diabetes Mellitus (T2DM) obese patients using another GLP1 receptor agonist (GLP1–RA) and switching to Semaglutide in Spain

BiosciAbstracts